PDF herunterladen
Am J Perinatol 2021; 38(13): 1435-1441
DOI: 10.1055/s-0040-1713406
Original Article

Plasma Citrulline as a Biomarker for Early Diagnosis of Necrotizing Enterocolitis in Preterm Infants

Nilima Jawale
1   Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York
,
Mallory Prideaux
1   Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York
,
Malavika Prasad
1   Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York
,
Malki Miller
1   Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York
,
Shantanu Rastogi
1   Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn, New York
2   George Washington University Hospital, Children's National Health System, Washington, DC
,
for Maimonides Neonatal Group › Institutsangaben Funding All phases of this study were supported by a resident research grant at Maimonides Medical Center.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Objective Citrulline synthesized by healthy enterocytes and decreases with injury. This work aimed to study plasma citrulline concentrations (CITs) as a biomarker to differentiate among infants presenting with early nonspecific signs and symptoms of necrotizing enterocolitis (NEC) with those who will develop NEC. Further to study the correlation between posttreatment CIT with time to full feeds (TTFF) and length of stay (LOS).

Study Design This is a prospective study which included infants < 32 weeks gestational age (GA) with 9 infants each in Group 1 (stage 2/3 NEC), Group 2 (with stage 1 NEC-like presentation), and Group 3 (healthy GA-matched infants). CIT was measured in Groups 1 and 2 within 24 hours of presentation and again in Group 1 after treatment.

Results The three groups were similar in clinical characteristics. Median CIT (µmol/L) in Group 1 (15.4 [interquartile range, IQR: 7.3–18.0]) was lower than Group 2 (22.2 [IQR: 18.3–27.3], p = 0.02) and Group 3 (24.9 [IQR: 19.8–31.9], p = 0.009). Posttreatment CIT in Group 1 did not correlate with TTFF (r = 0.15; p = 0.69) and LOS (r =  − 0.33; p = 0.38).

Conclusion CIT was lower in infants with NEC as compared with healthy controls and those infants with nonspecific signs of NEC. CIT after treatment does not correlate with TTFF and LOS.

Key Points

  • Citrulline is produced by enterocytes.

  • It is decreased in infants with necrotizing enterocolitis early in disease.

  • It can be used as a biomarker for early diagnosis of necrotizing enterocolitis.

Keywords

citrulline - necrotizing enterocolitis - preterm - biomarker - case–control

* Other members of Maimonides Medical Group are Alok Bhutada, MD, Michele Dyan, MD, Anju Gupta-Modak, MD, Panayot Filipov, MD, Tania Mangones, MD, and Melissa Tsai, MD.




Publikationsverlauf

Eingereicht: 24. März 2020

Angenommen: 14. Mai 2020

Artikel online veröffentlicht:
30. Juni 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Battersby C, Santhalingam T, Costeloe K, Modi N. Incidence of neonatal necrotising enterocolitis in high-income countries: a systematic review. Arch Dis Child Fetal Neonatal Ed 2018; 103 (02) F182-F189
    CrossrefPubMedGoogle Scholar
  • 2 Stoll BJ, Hansen NI, Bell EF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
    CrossrefPubMedGoogle Scholar
  • 3 Ganapathy V, Hay JW, Kim JH. Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med 2012; 7 (01) 29-37
    CrossrefPubMedGoogle Scholar
  • 4 Prasad M, Miller M, Bhutada A, Rastogi S. Citrulline: is it ready for primetime. its uses and limitations in neonatal medicine. J Neonatal Biol 2014; 3: 147 . doi:10.4172/2167-0897.1000147
    CrossrefPubMedGoogle Scholar
  • 5 Windmueller HG, Spaeth AE. Source and fate of circulating citrulline. Am J Physiol 1981; 241 (06) E473-E480
    PubMedGoogle Scholar
  • 6 Wu G, Bazer FW, Davis TA. et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009; 37 (01) 153-168
    CrossrefPubMedGoogle Scholar
  • 7 Crenn P, Coudray-Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000; 119 (06) 1496-1505
    CrossrefPubMedGoogle Scholar
  • 8 Bailly-Botuha C, Colomb V, Thioulouse E. et al. Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome. Pediatr Res 2009; 65 (05) 559-563
    CrossrefPubMedGoogle Scholar
  • 9 Rhoads JM, Plunkett E, Galanko J. et al. Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr 2005; 146 (04) 542-547
    CrossrefPubMedGoogle Scholar
  • 10 Papadia C, Sherwood RA, Kalantzis C. et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol 2007; 102 (07) 1474-1482
    CrossrefPubMedGoogle Scholar
  • 11 Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124 (05) 1210-1219
    CrossrefPubMedGoogle Scholar
  • 12 Woo HK, Kim E, Jung YH. et al. Reduced early dried blood spot citrulline concentrations in perterm infants with meconium obstruction of prematurity. Early Hum Dev 2015; 91 (12) 777-781
    CrossrefPubMedGoogle Scholar
  • 13 Becker RM, Wu G, Galanko JA. et al. Reduced serum amino acid concentrations in infants with necrotizing enterocolitis. J Pediatr 2000; 137 (06) 785-793
    CrossrefPubMedGoogle Scholar
  • 14 Ioannou HP, Diamanti E, Piretzi K, Drossou-Agakidou V, Augoustides-Savvopoulou P. Plasma citrulline concentrations in preterm infants with necrotizing enterocolitis. Early Hum Dev 2012; 88 (07) 563-566
    CrossrefPubMedGoogle Scholar
  • 15 Celik IH, Demirel G, Canpolat FE, Dilmen U. Reduced plasma citrulline concentrations in low birth weight infants with necrotizing enterocolitis. J Clin Lab Anal 2013; 27 (04) 328-332
    CrossrefPubMedGoogle Scholar
  • 16 Bell MJ, Ternberg JL, Feigin RD. et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 17 Demacker PNM, Beijers AM, Donnelly JP, Blijlevens NMA, vanden Ouweland JMW. Plasma citrulline measurements using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 387-392
    CrossrefPubMedGoogle Scholar
  • 18 Stultz JS, Tillman EM, Helms RA. Plasma citrulline concentration as a biomarker for bowel loss and adaptation in hospitalized pediatric patients requiring parenteral nutrition. Nutr Clin Pract 2011; 26 (06) 681-687
    CrossrefPubMedGoogle Scholar
  • 19 Piton G, Manzon C, Cypriani B, Carbonnel F, Capellier G. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker?. Intensive Care Med 2011; 37 (06) 911-917
    CrossrefPubMedGoogle Scholar
  • 20 Babu S, Prasad M, Miller M. et al. Use of serum citrulline concentrations from routine newborn screen as a biomarker for necrotizing enterocolitis. Pediatr Surg Int 2019; 35 (06) 715-722
    CrossrefPubMedGoogle Scholar
  • 21 Englund A, Rogvi RA, Melgaard L, Greisen G. Citrulline concentration in routinely collected neonatal dried blood spots cannot be used to predict necrotising enterocolitis. Acta Paediatr 2014; 103 (11) 1143-1147
    CrossrefPubMedGoogle Scholar
  • 22 Goossens L, Bouvry M, Vanhaesebrouck P, Wuyts B, Van Maele G, Robberecht E. Citrulline levels in a paediatric age group: does measurement on dried blood spots have additional value?. Clin Chim Acta 2011; 412 (7-8): 661-664
    CrossrefPubMedGoogle Scholar
  • 23 Hickey M, Georgieff M, Ramel S. Neurodevelopmental outcomes following necrotizing enterocolitis. Semin Fetal Neonatal Med 2018; 23 (06) 426-432
    CrossrefPubMedGoogle Scholar
  • 24 Peters JH, Wierdsma NJ, Teerlink T, van Leeuwen PA, Mulder CJ, van Bodegraven AA. The citrulline generation test: proposal for a new enterocyte function test. Aliment Pharmacol Ther 2008; 27 (12) 1300-1310
    CrossrefPubMedGoogle Scholar